The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Department of Trade and Industry Secretary Cristina Roque held a series of productive meetings with top executives of global ...

Information technology services firm Cognizant and transport and logistics firm A.P. Moller – Maersk are exploring investment opportunities in the Philippines, according to the Department of Trade and ...

(Alliance News) - Stocks were called to open higher in London on Friday morning, although UK consumer confidence has reportedly suffered a steep fall in recent weeks.

The major U.S. index futures are currently pointing to a higher open on Tuesday, with stocks likely to regain ground following the ...